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Summary and general discussion 
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 The overall aim of this thesis was to explore the potential relation of systemic markers 
of chronic low-grade inflammation with chronic transplant dysfunction (CTD) – leading to 
graft failure – and mortality after renal transplantation. A local inflammatory process in a 
tissue may lead to shedding of substances into the systemic circulation. The first part of 
the discussion of this thesis will be on markers of which variation in the systemic 
circulation may reflect variation in activity of ongoing local inflammatory processes in the 
transplanted kidney and future perspectives for research around these markers. A way to 
identify such markers is by investigating in a prospective study in renal transplant 
recipients whether they predict decline of renal function and/or occurrence of graft 
failure. If a marker would be predictive of mortality and not of decline of renal function or 
graft failure it may more reflect an ongoing systemic chronic inflammatory process, such 
as atherosclerosis, without particular involvement of the kidney. Such markers may be 
expected to predict (cardiovascular) mortality and/or cardiovascular events rather than 
decline of renal function and/or graft failure. The second part of the discussion of this 
thesis will be on such markers. 
 
SYSTEMIC MARKERS OF CHRONIC LOW-GRADE INFLAMMATION AND THE TRANSPLANTED 
KIDNEY 
 The two most important causes of graft loss longer after renal transplantation are 
CTD and death with a functioning graft, the latter mainly due to atherosclerotic 
cardiovascular disease.
1-4
 Recent insights suggest that CTD and cardiovascular disease 
share chronic low-grade inflammation and accelerated atherogenesis in their 
pathogenesis.
5-8
 For CTD, this suggestion is supported by the histological features of CTD, 
in which equivalents of atherosclerosis, including glomerulosclerosis, hyalinosis, and 
perivascular inflammation are prominent.
9
 Equivalents of atherosclerosis are, however, 
not the only common manifestation of ongoing low-grade inflammation in transplanted 
kidneys: the interstitium can also be importantly involved. A recent revision of the original 
Banff scoring system for international standardization of histological findings in biopsies of 
transplanted kidneys importantly acknowledges this.
10
 During the 9
th
 Banff conference 
held in 2007 a new lesion score, termed ‘ti’ (total interstitial inflammation), was added to 
the Banff schema. This lesion score uses quantitative criteria for mononuclear cell 
interstitial inflammation in total parenchyma (scarred and unscarred) scores.
10
  
 Many centers are reluctant to perform surveillance biopsies, as this is an invasive 
procedure, with an ever existing risk of complications, including intractable bleeding 
necessitating removal of the graft. As a consequence, currently, noninvasively estimates of 
glomerular filtration rate (e.g., creatinine clearance or plasma creatinine) and proteinuria 
are used for the identification of renal transplant recipients at increased risk for CTD.
11-13
 
However, once serum creatinine starts to rise or proteinuria develops, chronic structural 
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lesions are already present and it is usually too late for intervention.
1,14
 So, there is a great 
need for biomarkers that allow for earlier identification or prediction of CTD.
15
  
 In search for new biomarkers it is important to choose an appropriate end-point for 
analyses. For a first exploration biomarkers for of CTD leading to graft failure the 
appropriate end-point would intuitively be graft failure, with censoring for death. If, 
however, the supposed disease process is importantly shared with the end-point of death 
due to cardiovascular disease, a biomarker for this shared process – like CRP for the 
process of atherosclerosis, with the process of atherosclerosis provoking both decline of 
function of the transplanted kidney and development of cardiovascular disease – might 
come out with huge underestimation of predictive performance if graft failure is used as 
end-point, because in particular those with declining renal function would tend to die 
from cardiovascular disease before they can reach the end-point of graft failure, 
particularly if death with a functioning graft would be more common than graft failure 
itself. 
 
1.  C-reactive protein 
 C-reactive protein (CRP) is considered a marker of the chronic low-grade 
inflammatory component of the process of atherosclerosis. So, C-reactive protein as a 
potential early marker for CTD could be particularly susceptible to this “confounding” by 
early death due to accelerated atherosclerosis. To overcome this theoretical problem for 
C-reactive protein we investigated whether C-reactive protein is a predictor of change of 
renal function until end of follow-up. If patients died, last creatinine clearance during 
follow-up was used for evaluation. We indeed found that elevated concentrations of 
hsCRP independently predict accelerated deterioration in renal function (Chapter 3). Our 
study is the first to show that hsCRP can be used for early identification of renal transplant 
recipients at risk for deterioration of graft function, independent of other clinically 
accepted predictors of graft failure such as proteinuria.
16-18
 At the time we performed the 
analyses for this study, too few renal transplant recipients (RTR) had developed graft 
failure defined by need for return to dialysis or retransplantation to allow for multivariate 
evaluation. At that time, rate of death was approximately two times higher than rate of 
graft failure. Later, this difference in rate appeared to persist. Interestingly, in a later 
study, in which we evaluated plasma procalcitonin (PCT) as a potential marker for CTD, it 
appeared that hsCRP is not predictive of death-censored graft failure, but strongly 
predictive of death (Chapter 4), which could be in agreement with our hypothesis that 
hsCRP is a marker for the inflammatory component of the process of atherosclerosis 
which also involves the transplanted kidney. It was, however, not possible to investigate 
whether hsCRP was still predictive of change in renal function, because at the time there 
were enough graft failures and deaths to allow for multivariate evaluation our laboratory
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had shifted to another assay for plasma creatinine. 
 Like already outlined, the inflammatory process in transplanted kidneys frequently 
involves the interstitium in addition to vascular structures.
10
 Where it is currently even in 
biopsy studies still difficult – if not impossible – to determine whether the presence of 
inflammation is due to ongoing alloreactivity or not, this is even more difficult in 
epidemiological studies like the ones we perform. An important point that is not 
mentioned in reports on the Banff classification,
10,19-21
 is that presence of proteinuria in 
other proteinuric diseases like diabetic nephropathy, in which neither alloreactivity nor a 
primary inflammatory insult to the kidney are present, there is an interstitial inflammatory 
process characterized by the presence of macrophages, which strongly correlates with the 
magnitude of proteinuria/albuminuria.
22-24
 Thus, the presence of an interstitial 
inflammatory process in transplanted kidneys could well be aspecific and related to the 
extent to which filtered proteins induce inflammation in the interstitium of kidneys. 
Despite this potential non-specificity of the interstitial infiltrates, their presence offers 
opportunities for identification of new biomarkers for the ongoing inflammatory process 
that need not stringently be related to (peri)vascular inflammation like CRP supposedly is. 
Procalcitonin and hemopexin may be such biomarkers.  
 
2.  Procalcitonin 
 Procalcitonin (PCT) is best known as for being evaluated as a biomarker for bacterial 
infections and sepsis.
25,26
 Recently, however, it has been found that parenchymal cells 
stimulated by activated macrophages in infected tissues rather than peripheral blood 
mononuclear cells underlie very high concentrations of circulating PCT during sepsis.
27,28
 
PCT might thus be a marker of non-infectious inflammation driven tissue damage. In 
Chapter 4 we showed that PCT was independently associated with an increased risk for 
graft failure and, to a lesser degree, with mortality. Some of our findings in this study are 
of particular interest. First, the predictive performance for graft failure of PCT was similar 
to those of creatinine clearance and proteinuria, suggesting that measurement of PCT 
could be of additional value, next to measurement of creatinine clearance and proteinuria, 
for the identification of renal transplant recipients at risk for graft failure. Furthermore, 
the predictive performance of hsCRP, the prototypical acute phase reactant marker of 
inflammation, in predicting mortality was similar to that of PCT, while hsCRP was not a 
predictor for graft failure. This suggests that PCT is much more than hsCRP a specific 
marker for the ongoing inflammatory process local in the kidney. One of the possible 
underlying mechanisms linking increased PCT concentration to graft failure may lie in 
proteinuria. One of the hallmarks of proteinuric renal disease is infiltration of renal 
interstitial tissue by activated macrophages.
22-24
 Using adipocytes as a model for 
parenchymal cells of all kinds of tissues, it was recently demonstrated that parenchymal 
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cells secrete PCT in response to stimulation by activated macrophages.
27,28
 Thus, our 
finding of high circulating PCT concentrations to predict graft failure may be a reflection of 
the release of PCT into the circulation by renal parenchymal cells in response to renal 
macrophage infiltration and activation in relation to proteinuria. Importantly, however, in 
our secondary analyses, we found PCT to be particularly predictive for development of 
graft failure in RTR without proteinuria. One possibility is that the cascade with 
macrophage activation and interstitial inflammation is already fully activated when the 
amount of protein in urine is still below the upper limit of the reabsorption capacity of the 
tubular epithelial cells. There is recent evidence that much more protein is filtered than 
has previously been thought and that active processing by tubular epithelial cells prevents 
it from appearing in urine.
29-31
 The concentration of PCT will then already be elevated in 
RTR when proteinuria is not yet detectable. This leads to the hypothesis that PCT is not 
only a biomarker for the existence of proteinuria, but could also be an early marker for a 
tendency for development of proteinuria. One way to substantiate this possibility would 
be by demonstration of a relationship between PCT and urinary albumin excretion in the 
general population, e.g. in the Groningen Prevention of End-stage Renal and Vascular 
Disease (PREVEND) study. Another possible mechanism linking PCT to development of 
graft failure may lie in alloreactivity. An ongoing chronic low-grade immunological 
response against non-self epitopes in the transplanted kidney may provoke an ongoing 
inflammatory process in the transplanted kidney which may lead to increased synthesis 
and release of PCT into the circulation from parenchymal renal cells and also from 
immune cells in the kidney. If proteinuria would be the trigger for PCT release from the 
kidney into the circulation, PCT should also be a marker of development of end-stage renal 
disease in non-inflammatory, non-transplant proteinuric diseases such as for instance 
diabetic nephropathy. If alloreactivity would be the trigger, PCT is more likely to not be a 
marker of development of end-stage renal disease in diabetic nephropathy. PCT might 
then also be promising as a marker of allograft dysfunction in other transplant populations 
such as, for example, lung, heart, liver transplant recipients.  
 It has been shown that immunoneutralization by an antiserum that is reactive to PCT 
ameliorates the symptomatology and also markedly improves survival of severely infected 
animals (i.e., hamsters and pigs).
32-34
 It may therefore also be interesting to intervene on 
PCT in RTR with high PCT concentrations and high risk for development of graft failure in 
the near future.  
 
3.  Hemopexin activity 
 Hemopexin is mainly expressed in liver, and belongs to the acute phase reactants, the 
synthesis of which is induced after inflammation.
35
 Recent studies suggest a role for 
hemopexin, an acute phase protein, in inflammation and kidney damage. We 
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hypothesized that hemopexin might be involved in non-infectious inflammation driven 
deterioration of renal allograft function. In chapter 5 we showed that hemopexin activity 
late after transplantation is associated with a higher risk for graft failure in renal 
transplant recipients independent of possible confounders. There is accumulating 
evidence pointing to hemopexin as a key player in determining integrity of the glomerular 
filtration barrier. First, hemopexin infusion in rats induces reversible proteinuria.
36
 Second, 
in vitro data have indicated that hemopexin is involved in the cytoskeleton reorganisation 
of human podocytes, and is capable of increasing glomerular permeability by degrading 
the glycocalyx.
37
 In humans, the idea is supported by a study in children with minimal 
change nephrotic syndrome having higher levels of activated hemopexin.
38
 However in 
our study the predictive role of hemopexin activity for graft failure was independent of 
proteinuria, which suggests that proteinuria does not play a(n important) role in the 
mechanism underlying the association of hemopexin activity with increased graft failure. 
There are several putative underlying mechanisms explaining the association of 
hemopexin activity with increased risk for graft failure after renal transplantation. First, 
the association might be causal, which would mean that higher hemopexin activity itself 
leads to graft failure. Second, hemopexin activity may be a marker of an  inflammatory 
process in the kidney. Inflammation in the kidney would then lead to local increased 
hemopexin activity, with hemopexin activity only acting as a marker for an increased 
tendency for development of graft failure after renal transplantation. More studies are 
needed to acquire further understanding of the role of hemopexin activity in development 
of graft failure. If hemopexin activity would be actively involved, it could lead to 
identification of new therapeutic agents and strategies. 
 
SYSTEMIC INFLAMMATORY PROCESSES AND MARKERS OF INFLAMMATION IN RENAL 
TRANSPLANT RECIPIENTS 
1.  Determinants of CRP in renal transplant recipients 
 In renal transplant recipients, slightly elevated levels of CRP have recently been 
demonstrated to be an independent predictor of coronary heart disease and total 
mortality.
39,40
 Importantly, a recent study has identified post-transplant CRP also as a 
predictor of chronic allograft nephropathy in a univariate analysis.
41
 However, in renal 
transplant patients it is not known what factors determine plasma CRP concentrations. In 
chapter 2 we have shown that waist circumference, as a measure of obesity, is the 
strongest, modifiable risk factor for a high hsCRP in renal transplant recipients.
42
 The 
association of CRP with measures of obesity have also been shown in the general 
population and in patients with various degrees of renal insufficiency.
43-51
 Adipose tissue is 
nowadays regarded as a very active endocrine organ, which secretes numerous hormones 
and pro-inflammatory cytokines, including tumor necrosis factor-α and IL-6 into the 




 Approximately 25% of basal circulating IL-6 originates in human adipose 
tissue,
54
 with production in intra-abdominal fat 3 times that of subcutaneous fat.
55
 These 
pro-inflammatory cytokines stimulate the liver in synthesis and secretion of CRP. The 
majority (60%) of renal transplant recipients in the United States are currently overweight 
or obese at the time of transplantation. Furthermore, many renal transplant recipients 
experience a 10% weight gain after transplantation,
56
 predominantly because of an 
increase in fat mass.
57
 Although there have been only few large, controlled studies that 
have rigorously assessed the effect of weight loss on CRP level, the studies that have been 
done suggest that weight loss may be an effective nonpharmacologic strategy for lowering 
CRP level.
58
 Whether this is also true in renal transplant recipients has to be shown in 
future studies 
 
2.  Cytomegalovirus 
 Cytomegalovirus (CMV) is the most important pathogen after renal transplantation 
occurring in 20 to 60 percent of the renal transplant recipients.
59
 In part this reflects the 
ubiquitous nature of the virus as it is estimated that 60 to 70 percent of the general 
population are infected with CMV.
60
 However, renal transplant recipients are more 
susceptible for reactivation of latent CMV compared to the general population. This 
occurs in particular in the first months after transplantation as a consequence of a 
temporary disruption of an otherwise existing balance between immunological 
surveillance and viral replication by treatment with cytotoxic drugs and antilymphocyte 
antibody therapy and by systemic infection and inflammation.
3
 CMV reactivation from 
latency and primary infection are risk factors for both immunological rejection and 
mortality in the first year after transplantation.
61-66
 Relevance of CMV as an urgent 
medical problem slowly diminishes with time after transplantation in conjunction with 
return to latency. However, the virus may continuously smoulder under conditions of 
chronic immunosuppression, in particular in inflamed tissues.
67,68
 It has indeed been 
shown that latent CMV can be locally active in a transplanted organ with ongoing low-
grade alloreactivity, without systemic signs of activity in the chronic phase after 
transplantation.
69
 In Chapter 8 it is described that both graft and recipient survival is 
significantly better in CMV seronegative renal transplant recipients compared to CMV 
seroconverted or seropositive renal transplant recipients when CMV serology is 
determined more than one year after transplantation. Furthermore, renal transplant 
recipients who are CMV IgG seropositive are at 2.7 times higher risk for graft failure than 
for death. These findings suggest that latent CMV is more active in a transplanted organ, 
potentially in association with chronic ongoing low-grade alloreactivity, or in kidneys in 
general. An important implication of this study would be that there should be more focus 
on matching for CMV status because, apparently, it is not only important to prevent CMV 
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disease, but to prevent occurrence of CMV infection at all. Current treatment guidelines 
recommend CMV prophylaxis for all recipients of solid organ transplants, who receive 
immunosuppression with antilymphocyte antibody products and for CMV negative 
recipients of CMV positive organs.
70-72
 However, it has been shown that up to 30% of CMV 
seronegative recipients receiving an organ from a CMV seropositive donor develop CMV 
disease after cessation of CMV prophylaxis (i.e., delayed-onset primary CMV disease).
72,73
 
This suggests that the virus may continuously smoulder during prophylactic therapy and is 
reactivated after cessation of CMV prophylactic therapy. Another option to prevent CMV 
after renal transplantation is the development of a safe and effective vaccine. Several 
earlier trials tested a live, attenuated CMV vaccine in patients before renal transplantation 
but failed to show benefits in reducing the incidence of CMV disease. However, severe 
CMV disease was less frequent among the vaccinated CMV seronegative patients who 
received a kidney from a seropositive donor, and survival was significantly improved.
74
 
Other recombinant vaccines from viral particles remain in preclinical or earlier clinical 




3.  Serum albumin as negative acute phase protein  
 Hypoalbuminemia is common after renal transplantation.
78,79
 Serum albumin is a 
negative acute phase protein, and hypoalbuminemia may therefore be reflecting ongoing 
chronic low-grade inflammation.
80,81
 Other potential explanations for hypoalbuminemia 
are poor nutritional status and loss of protein, in particular with proteinuria.
80,81
 Low 





 in renal transplant recipients. In the cross-sectional part of Chapter 6, we 
found independent inverse associations of serum albumin with hsCRP and urinary protein 
excretion. Prospectively, we found that RTR with low serum albumin concentrations at 
baseline are at increased risk for graft failure and mortality during follow-up, which is in 
line with existing literature.
78,79,82-84
 Despite the cross-sectional associations of serum 
albumin with hsCRP and urinary protein excretion at baseline, the association of serum 
albumin with graft failure was not explained by hsCRP, while the association of serum 
albumin with mortality was explained by hsCRP only to a very small extent (change in 
hazard ratio from 0.39 to 0.41). Importantly, we found that the association between 
serum albumin and graft failure was only present in RTR with proteinuria. This observation 
suggests that low albumin concentrations are not a risk factor for graft failure by 
themselves. Rather, it is strongly suggestive that proteinuria is involved. One reason may 
be that severity of proteinuria in some RTR is underestimated as a consequence of errors 
in collecting 24h urine samples. It is well-known that 24h urine collection is prone to 
collection errors.
85-88
 Another reason may be that low albumin concentrations in the 
presence of proteinuria are an indication of detrimental effects or urinary loss of peptides 
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undetected by urinary protein assays as a consequence of tubular processing.
29-31
 For 
mortality, the impact of serum albumin was similar in RTR with and without proteinuria 
suggesting that malnutrition might be an important pathway linking serum albumin to 
mortality. 
 
4.  Endothelial dysfunction as marker of the inflammatory process of the vascular wall 
 Activation of the inflammatory cascade leads to endothelial dysfunction (ED) which 
sets the stage for both initiation and progression of atherosclerotic lesions.
89
 Besides 
inducing atherosclerosis, ED leads to increased vascular permeability for proteins resulting 
in, for example, proteinuria. Proteinuria is an established predictor of mortality, in 
particular cardiovascular mortality, in several populations, including renal transplant 
recipients.
17,90-96
 The association of proteinuria with ED is considered to be a mechanism 
underlying the elevated mortality in proteinuria.
97-99
 However, whether ED is involved in 
the prognostic impact of proteinuria in renal transplant recipients is unknown. In Chapter 
7 we show that urinary protein excretion and concentrations of sICAM-1 and sVCAM-1, as 
markers of ED, independently predict mortality late after transplantation. Furthermore, 
renal transplant recipients with proteinuria and high concentrations of sICAM-1 or sVCAM-
1 appear to be at highest risk for death compared to renal transplant recipients without 
proteinuria and with low concentrations of sICAM-1 or sVCAM-1. These results suggest 




 In conclusion, we have investigated role of chronic low-grade inflammation in CTD 
and mortality after renal transplantation. One of the main findings is that hsCRP can be 
used as an early marker accelerated deterioration of graft function. We furthermore have 
shown that procalcitonin, to date only known to reflect microbial inflammation, is a strong 
predictor of graft failure, independent of creatinine clearance and proteinuria. The overall 
findings in this thesis support the growing notion that inflammation plays a role in the 
development of graft failure after renal transplantation. 
 Future studies are needed to investigate the mechanism underlying the role of 
chronic low-grade inflammation in the deterioration of renal function, the development of 
CTD, and mortality and whether treatment of chronic low-grade inflammation has a 
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